Providing clarity on patient rights for informed consent in clinical investigations, the US Food and Drug Administration (FDA) has issued its final guiding document as of August 15, 2023. Titled ‘Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors’ (final guidance), this decisive documentation finalizes, with new examples and minuscule updates and alterations, the FDA’s prior draft guidance from July 15, 2014, known as the ‘Informed Consent Information Sheet: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors.’
At its core, this new guidance is intended to facilitate better understanding and compliance relating to the process of informed consent in clinical investigations. Ensuring that subjects participating in these investigations have a comprehensive understanding of the intent, methodologies, and potential risks is of critical importance.
The ‘Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors’ seeks to mitigate any uncertainties in the process, offering fresh examples to help guide Institutional Review Boards (IRBs), clinical investigators, and sponsors in the practice of informed consent. Aiming to promote transparency and ethical practices, the document enhances the FDA’s mission to protect public health by assuring the safety and effectiveness of drugs, medical devices, and other FDA-regulated products.
For attorneys, in-house counsel, and other legal professionals working in the pharmaceutical, biotech, and medical device sectors, this finalized guidance provides clear benchmarks for regulatory compliance in clinical studies. Indeed, the document is not only an essential asset for legal teams within such corporations but is also of significant value to those legal practitioners advising clients in these sectors.
For comprehensive information regarding this final guidance, you can access the complete report here.